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Exacerbations are a hallmark of chronic obstructive pulmonary disease (COPD). Evidence suggests the pres-
ence of substantial between-individual variability (heterogeneity) in exacerbation rates. The question of whether
individuals vary in their tendency towards experiencing severe (versus mild) exacerbations, or whether there is
an association between exacerbation rate and severity, has not yet been studied. We used data from the
MACRO Study, a 1-year randomized trial of the use of azithromycin for prevention of COPD exacerbations
(United States and Canada, 2006–2010; n = 1,107, mean age = 65.2 years, 59.1% male). A parametric frailty
model was combined with a logistic regression model, with bivariate random effects capturing heterogeneity in
rate and severity. The average rate of exacerbation was 1.53 episodes/year, with 95% of subjects having a
model-estimated rate of 0.47–4.22 episodes/year. The overall ratio of severe exacerbations to total exacerba-
tions was 0.22, with 95% of subjects having a model-estimated ratio of 0.04–0.60. We did not confirm an associ-
ation between exacerbation rate and severity (P = 0.099). A unified model, implemented in standard software,
could estimate joint heterogeneity in COPD exacerbation rate and severity and can have applications in similar
contexts where inference on event time and intensity is considered. We provide SAS code (SAS Institute, Inc.,
Cary, North Carolina) and a simulated data set to facilitate further uses of this method.
chronic obstructive pulmonary disease; nonlinear mixed models; random effects; randomized trials; survival
analysis
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; OR, odds ratio.
Chronic obstructive pulmonary disease (COPD) is a
common chronic disease of the airways characterized by
the progressive loss of lung function (1). COPD is the third
leading cause of years of life lost in the United States (2),
and evidence suggests that its burden in comparison with
other common chronic diseases is increasing (3). The main
symptoms of COPD include shortness of breath, cough,
and sputum (4). Periods of intensified disease activity (typi-
cally short in duration), referred to as exacerbations, are a
prominent feature of COPD and a major cause of morbid-
ity, mortality, and economic burden (4). COPD exacerba-
tion is the number 1 cause of medical hospitalizations in
Canada (5).
The average annual rate of exacerbations in well-
characterized COPD cohorts is between 0.85 and 1.30 epi-
sodes (6–8), but individual patients vary significantly in
their propensity to experience exacerbations, with the “fre-
quent exacerbator” trait considered to be relatively stable
over time (7). Exacerbations also vary in severity, with current
consensus reports categorizing them as mild (symptom-based),
moderate (requiring a physician visit and/or treatment with
oral corticosteroids), or severe (requiring hospitalization) (9).
Approximately 20% of COPD exacerbations are severe (10).
Whether individuals vary in their tendency to experience
more severe exacerbations versus milder exacerbations largely
remains unknown.
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Prevention, early detection, and appropriate treatment of
exacerbations are a focal point of attention in COPD care
and research. In the presence of significant between-
individual variability (heterogeneity) in the rate and sever-
ity of exacerbations, it is likely that the benefit-risk profile
of prevention and early detection strategies for exacerba-
tions will be a function of individuals’ background exacer-
bation risk and their propensity to experience severe
exacerbations. Use of the ubiquitous proportional hazards
model, with time to first exacerbation as the outcome, is a
common mode of inference in contemporary clinical trials
of COPD. While it is robust in estimating treatment effect
in randomized controlled trials, this analytical method falls
short of providing other features, such as background rate
of exacerbations or the shape of the incidence function, to
enable predictions about the rate and (absolute or relative)
duration of time to future events for a given patient. As
mentioned by Cox et al. (11), making such informative pre-
dictions has been hindered by the widespread use of semi-
parametric proportional hazards models.
Parametric frailty models are a class of survival models
that enable the analysis of recurrent events, can explicitly
model heterogeneity across individuals through random-
effect terms, and can quantify the incidence rate and the shape
of the incidence function, thus providing all of the quantities
necessary for specification of the complete natural history of
recurrent events (12). While there are dedicated computer
routines to fit certain groups of such models, general nonlin-
ear mixed-model optimizers, such as PROC NLMIXED in
SAS (SAS Institute, Inc., Cary, North Carolina), give the ana-
lyst the necessary power to fully specify the likelihood func-
tion for statistical inference in such models (see chapter 15 in
SAS for Mixed Models (13)). The added benefit of such
generic optimizers is that the model can be modified to better
address the specific question at hand (14).
Our overall objective in the present study was to quan-
tify jointly the heterogeneity in the rate and severity of
COPD exacerbations, with the specific objective of testing
whether there is an association between exacerbation rate
and severity. Our hypothesis was that persons who fre-
quently experience exacerbation also tend to experience a
higher proportion of severe exacerbations. This hypothesis
was based on the assumption that being more vulnerable to
the causes and drivers of COPD exacerbation (inflamma-
tion and/or infection (15)) would increase individuals’ risk
of experiencing more frequent exacerbations as well as
more severe events. A modification of parametric shared
frailty models enabled us to conduct simultaneous model-
ing of the rate and severity of exacerbations to address
these objectives.
METHODS
The data
This study was approved by the University of British
Columbia’s Human Ethics Board. The analysis was based
on the data from the MACRO Study (16), a multicenter
North American clinical trial designed to determine whether
azithromycin, an antibiotic, was effective in reducing COPD
exacerbations. Details on the study and its findings are pre-
sented elsewhere (16). In brief, the study randomized
1,142 patients to placebo or azithromycin (250 mg/day).
Eligible patients included those aged 40 years or older
with a clinical diagnosis of COPD who were either using
continuous supplemental oxygen therapy or had received
systemic glucocorticoids, had visited an emergency room,
or had been hospitalized for COPD exacerbation within
the previous year. The primary endpoint was time to first
exacerbation, categorized into mild (requiring sympto-
matic treatment), moderate (requiring oral corticosteroids),
severe (requiring inpatient care), or very severe (requiring
intubation). The time of exacerbation was considered to be
the date on which treatment was initiated. Follow-up time
was 385 days.
Statistical analysis: joint modeling of rate and severity
of exacerbations
We specified a joint survival-logistic model to simulta-
neously estimate the association between clinical features
and the rate and severity of exacerbations. The framework
used is generally similar to one described by Berridge and
Whitehead (17), who investigated the efficacy of a treat-
ment for headache in terms of both time to recurrence of
headaches and their severity. The authors fitted a nonpara-
metric proportional hazards model for time to first event
and separately fitted an ordinal regression model for sever-
ity categories. In the present work, we used a joint para-
metric recurrent-event and logistic regression model to
enable full quantification of exacerbation incidence and
severity and their correlation. Compared with the alterna-
tive framework of modeling exacerbations of different se-
verities as separate types of events, this framework is more
conceptually aligned with the conventional wisdom that ex-
acerbations share a common pathophysiology (15). In addi-
tion, while enabling us to model exacerbation severity, this
model retained the ability to allow direct inferences on the
occurrence of any exacerbations, which is the outcome of
interest in many COPD studies (18). Finally, this fully
parametric model enabled us to specify the likelihood (see
Web Appendix 1, available at http://aje.oxfordjournals.org/)
and to use generic algorithms that are developed for fitting
nonlinear mixed models (13).
The rate component. The basis of our model was a
parametric random-effects (frailty) accelerated failure time
model. For the ith individual, the instantaneous exacerba-
tion rate at time t (hazard) is
λ ( ) = θ λ ( θ ) θ = β +t t e. . , with ,Xi i i i z0 . i i
with Xi being the vector of observed, time-fixed character-
istics (covariates), β the vector of regression coefficients,
and zi an unobserved normally distributed zero-mean ran-
dom-effect term that is specific to each person and captures
between-individual variability in exacerbation rate over and
beyond the variability due to observed characteristics. λ0 is
the baseline hazard function. The association between co-
variates and the event of interest in accelerated failure time
models is modeled in terms of “speeding up” or “slowing
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down” the time to the event (19). Accelerated failure time
models are popular models for predicting time to events
and event rates. For example, they were the basis of the
original Framingham Study risk prediction equations for
cardiovascular disease (20).
Time zero in this analysis was the randomization date.
Because our interest was in estimating the cumulative inci-
dence of exacerbation from this time onward, a “total time”
model for recurrent events was used (21). The total time
model enables quantification of complete event incidence
by specifying the hazard function from a given point for-
ward, as opposed to the “gap time” analysis, which resets
the hazard function after each event (21). The total time
approach does not directly model any association between
the occurrence of an exacerbation and the risk or severity
of future ones. Instead, the model assumes that individuals
have intrinsic properties determining the relationship
between their exacerbation rate and severity, enabling sta-
tistical testing of the study’s specific hypothesis.
For a parametric survival model, a baseline hazard (or
survival) function needs to be specified (11). Common
choices include Weibull (which includes the constant-
hazard exponential survival model as a special case),
lognormal, and log-logistic survival functions (11). We
evaluated all such functions and used the Akaike
Information Criterion as an objective measure to find
the best-fitting function (22). We also visually inspected the
predicted cumulative number of exacerbations versus the
observed cumulative number of exacerbations to check
the goodness-of-fit of the chosen survival function. With
the Weibull survival function, the accelerated failure time
model is also a proportional hazards model (23, p. 45), and
thus regression coefficients can be presented in terms of
both the acceleration factor and the more familiar hazard
ratio (Web Appendix 1) (19). Due to the small number of
deaths, and in line with the primary analysis of the
MACRO Study (16), we did not adjust for the competing
risk of death in the main analysis but investigated its effect
in a sensitivity analysis.
The severity component. The second component was a
random-effects logit (logistic) model for the severity of ex-
acerbations. While this could be a multilevel ordinal logit
model capturing the 4 levels of exacerbation severity, we
felt that the most natural distinction lies between severe-to-
very-severe exacerbations and mild-to-moderate exacerba-
tions, as the former type requires expensive inpatient care,
while the latter can be managed in a physician’s office or
by the patient at home. Thus, we used a binary categoriza-
tion contrasting severe/very severe (referred to collectively
as severe) exacerbations with mild/moderate (referred to
collectively as mild) exacerbations. This model predicts the
probability that the jth exacerbation in the ith individual
(denoted by Yi,j) will be severe (coded as 1, compared with
0 for mild exacerbation):
( = ) = θ′
+ θ′
θ′ = β′ + ′P Y e1
1
, with ,Xi j
i
i
i
z
,
. i i
with Xi being covariates (all time-fixed), β′ the regression
coefficients, and ′z i a normally distributed zero-mean
random-effect term that is specific to each person and cap-
tures between-individual variability in the proportion of
severe exacerbations (out of the total number). Regression
coefficients from this component can be expressed in terms
of odds ratios associating the covariate with the probability
of an exacerbation’s being severe. Persons with at least 1
exacerbation contribute to the severity component.
The same set of covariates was used for both the survival
and logistic components and consisted of age at baseline,
sex, treatment group assignment, smoking status at baseline
(current smoker vs. ex-/never smoker), whether the patient
had been hospitalized for a COPD exacerbation during the
12-month period before the study, whether the patient had
received home oxygen therapy during the 12-month period
before the study, degree of airflow obstruction (measured
in terms of forced expiratory volume in 1 second at base-
line; the higher the forced expiratory volume in 1 second,
the lower the degree of obstruction), and COPD-specific
health status (captured by total score on the St. George’s
Respiratory Questionnaire at baseline; the higher the score,
the lower the health status) (24).
To examine the extent of heterogeneity, we calculated
the coefficient of variation, defined as the ratio of the stan-
dard deviation to the mean, for model-estimated individu-
alized exacerbation rate as well as the proportion of severe
exacerbations. We also determined the lower and upper
bounds of these quantities that contained 95% of the sam-
ple. Individualized rates and proportions were calculated
using the maximum-likelihood estimates of the fixed-
effect and empirical Bayes estimates of the random-effect
terms (13).
This framework was also used to test the hypothesis that
across individuals, there is a relationship between the rate
of exacerbation and the severity of exacerbation. The 2
random-effect terms are governed by 3 parameters (2 vari-
ance parameters and 1 covariance parameter). A positive
(negative) covariance indicates that persons with a higher
rate of exacerbation tend to have a higher (lower) risk of
their exacerbations being severe.
We performed sensitivity analyses to evaluate the robust-
ness of the results. These included treating death as an
event to evaluate its impact as a competing risk (25), as
well as fitting the rate and severity components separately.
SAS, version 9.4, was used for statistical analysis, with
PROC NLMIXED used for maximum likelihood estima-
tion (13). All tests of statistical significance were 2-sided at
a significance level of 0.05. The SAS code and a simulated
data set are provided in Web Appendix 2 and on our web-
site (http://resp.med.ubc.ca).
RESULTS
Of the 1,142 persons recruited, 1,117 MACRO partici-
pants had at least 1 follow-up visit and were included in
the original analysis (16). Of these, 10 had missing or
invalid data for outcome or independent variables and were
excluded from this analysis. The final sample constituted
1,107 individuals (mean age = 65.2 years; 59.1% male)
who were followed for a mean of 343.7 days (0.94 years)
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and experienced 1,601 exacerbations, 348 (21.7%) of them
severe. The rate of exacerbation was 1.53 episodes per
patient-year for any exacerbation and 0.33 for severe ex-
acerbations. The baseline characteristics of the final sample
and their follow-up statistics are provided in Table 1.
During the course of the study, 21 and 18 persons died in
the placebo and treatment groups, respectively.
Among the 3 different survival functions examined, the
best fit was from the Weibull model, both in terms of the
Akaike Information Criterion (Web Table 1) and in terms of
the observed versus expected cumulative number of exacer-
bations during follow-up (Figure 1). As such, the Weibull
model was chosen, and the results are reported in terms of
both time acceleration and hazard ratio. The match in the
observed and expected cumulative number of severe exacer-
bations also indicated that the logistic regression model could
explain the distribution of severity in the sample. The addi-
tion of random-effect terms for both rate and severity further
improved model fit, indicating the presence of unexplained
heterogeneity in both the rate and severity of exacerbations
(Web Table 1). The estimated shape parameter of the Weibull
distribution was 0.967 (95% confidence interval (CI): 0.920,
1.013). Because the Weibull model with a unity shape parame-
ter corresponds to the exponential model, the incidence func-
tion of exacerbations was compatible with a constant rate over
the study period.
Table 2 provides the maximum likelihood estimates of
model parameters. Treatment with azithromycin reduced
the rate of exacerbation by 23% (hazard ratio (HR) = 0.77,
95% CI: 0.67, 0.89; P < 0.001) but had no effect on the
severity of exacerbations (odds ratio (OR) = 0.93, 95% CI:
0.62, 1.38; P = 0.703). Among covariates, male sex was
associated with a lower rate of exacerbation (HR = 0.84,
P = 0.019) but a higher likelihood of exacerbations being
severe (OR = 1.84, P = 0.005). A history of COPD-related
hospital admission in the previous year was associated with
a higher rate of exacerbation (HR = 1.48, P < 0.001) as
well as increased severity of exacerbations (OR = 2.93,
Table 1. Baseline Characteristics and Follow-up Statistics for 1,107 Chronic Obstructive Pulmonary Disease Patients, According to Treatment
Status, MACRO Study, 2006–2010a
Variable
Placebo Group (n = 552) Treatment Group (n = 555) Total (n = 1,107)
No. of
Persons % Mean (SD)
No. of
Persons % Mean (SD)
No. of
Persons % Mean (SD)
Baseline Characteristics
Male sex 327 59.2 327 58.9 654 59.1
Age, years 65.5 (8.5) 64.8 (8.7) 65.2 (8.6)
Current smoker 127 23.0 117 21.1 244 22.0
Oxygen therapy during prior year 323 58.5 332 59.8 655 59.1
Hospitalization during prior year 281 50.9 276 49.7 557 50.3
FEV1, L 1.12 (0.52) 1.10 (0.50) 1.11 (0.51)
SGRQ scoreb 51.7 (16.2) 52.8 (16.3) 50.6 (16.4)
Follow-up Statistics
Follow-up time, years 0.94 (0.18) 0.94 (0.18) 0.94 (0.18)
No. and rate of COPD exacerbationsc
Total 878 1.69 723 1.39 1,601 1.53
Mild/moderate 681 1.31 572 1.10 1,253 1.20
Severe/very severe 197 0.38 151 0.29 348 0.33
Exacerbation frequencyd
0 172 31.2 238 42.9 410 37.0
1 166 30.1 144 25.9 310 28.0
2 85 15.4 72 13.0 157 14.2
3 56 10.4 48 8.7 104 9.4
4 30 5.4 19 3.4 49 4.4
5 19 3.4 14 2.5 33 3.0
≥6 24 4.3 20 3.6 44 4.0
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; SD, standard deviation; SGRQ,
St. George’s Respiratory Questionnaire.
a Data are presented as mean (SD) for continuous variables and number of subjects (% of column total) for dichotomous variables, except
where noted.
b Between 0 and 100, with a higher score indicating worse status.
c Numbers in the % column show the annual rate of exacerbations (episodes/patient).
d Number of participants with the specified number of COPD exacerbations during follow-up.
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P < 0.001). Other factors that were significantly associated
with exacerbation rate included being a smoker at baseline
(HR = 0.82, P = 0.036), baseline forced expiratory volume
in 1 second (per 1-L increase, HR = 0.82; P = 0.014), and
COPD-related health status (per 10-unit increase in St.
George’s Respiratory Questionnaire score, HR = 1.12; P <
0.001). Among these variables, only the latter was associated
with severity (per 10-unit increase, OR = 1.15; P = 0.030).
There was substantial unexplained variability (het-
erogeneity) in both the rate and severity of exacerbations
(variance for random-effect terms: 0.55 (95% CI: 0.41,
0.68; P < 0.001) for rate and 2.25 (95% CI: 1.24, 3.25;
P < 0.001) for severity). The correlation coefficient for the
random-effect terms for rate and severity was −0.18 (95%
CI: −0.40, 0.03; P = 0.099); thus, the null hypothesis that
there is no association between exacerbation rate and sever-
ity could not be rejected at the significance level of 0.05.
Figure 2 provides a histogram of the distribution of the
individualized rate of exacerbations and the individualized
proportion of severe exacerbations (out of the total number).
The coefficient of variation for the individualized rate of
exacerbation was 0.69. Ninety-five percent of the subjects
had an individualized rate between 0.47 episodes per year
and 4.22 episodes per year. The coefficient of variation for
Table 2. Maximum-Likelihood Estimates of the Parameters in a Joint Rate-Severity Model of Chronic Obstructive Pulmonary Disease
Exacerbations, MACRO Study, 2006–2010
Variable
Rate Component Severity Component
HR 95% CI β for AFTa 95% CI P Valueb OR 95% CI P Valueb
Treatment group (vs. placebo) 0.77 0.67, 0.89 1.30 1.13, 1.50 <0.001 0.93 0.62, 1.38 0.703
Male sex (vs. female) 0.84 0.72, 0.97 1.20 1.03, 1.40 0.019 1.84 1.20, 2.82 0.005
Age at baseline (per 10-year increase) 0.96 0.88, 1.05 1.05 0.96, 1.14 0.332 0.97 0.76, 1.24 0.799
Current smokerc at baseline 0.82 0.68, 0.99 1.23 1.01, 1.48 0.036 1.29 0.76, 2.16 0.343
Oxygen therapyc during year before baseline 1.05 0.90, 1.23 0.95 0.81, 1.11 0.517 1.26 0.80, 1.98 0.320
Hospitalizationc during year before baseline 1.48 1.28, 1.70 0.67 0.58, 0.77 <0.001 2.93 1.92, 4.47 <0.001
Baseline FEV1 (per 1-L increase) 0.82 0.69, 0.96 1.23 1.04, 1.46 0.014 0.74 0.46, 1.21 0.234
SGRQ scored (per 10-unit increase) 1.12 1.07, 1.17 0.89 0.85, 0.93 <0.001 1.15 1.01, 1.31 0.030
Abbreviations: AFT, accelerated failure time; CI, confidence interval; FEV1, forced expiratory volume in 1 second; HR, hazard ratio; OR, odds
ratio; SGRQ, St. George’s Respiratory Questionnaire.
a The regression coefficient y for covariate x means that persons with x = 1 experience as many exacerbations in y time units as persons
with x = 0 experience in 1 time unit (unlike the case with the HR, the higher the acceleration factor the lower the event rate).
bP values were considered significant at the 0.05 level. All P values and confidence limits were computed from the final Hessian matrix
based on a t distribution with default degrees of freedom (number of subjects minus number of random effects) in SAS NLMIXED.
c Binary variable.
d Between 0 and 100, with a higher score indicating worse status.
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Figure 1. Observed number of chronic obstructive pulmonary disease (COPD) exacerbations versus predicted number of exacerbations (A)
and number of severe exacerbations (B) during follow-up time, MACRO Study, 2006–2010. The lower slope of the curve on the right side of the
x-axis is due to attrition occurring towards the end of the study.
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the individualized proportion of severe exacerbations was
0.81, with 95% of the sample having an individualized pro-
portion between 0.04 and 0.60.
Results of sensitivity analyses are provided in Table 3.
In general, the major findings of the study remained robust
against alternative assumptions and design features.
DISCUSSION
Using a joint frailty-logistic model, we quantified the
extent of heterogeneity in the rate and severity of COPD
exacerbations and quantified the association between sev-
eral clinical features and exacerbation rate and severity.
The frailty (rate) component of the model, which modeled
the cumulative incidence of exacerbations during follow-
up, produced an effect estimate for treatment with azithro-
mycin (HR = 0.77) that was slightly less favorable than the
effect reported in the original study (HR = 0.73), which
modeled duration of time to the first exacerbation (16). The
results of the logistic (severity) component did not support
the presence of an association between treatment and sever-
ity of exacerbations. We documented substantial levels of
heterogeneity in both exacerbation rate and severity over
and beyond variability due to clinical characteristics and
treatment group assignment. The joint survival-logistic
model could be fitted in standard statistical software and
can have potential applications in many other contexts
where time to recurrent events and intensity of events are
both of interest.
Our a priori hypothesis of a positive association between
exacerbation rate and severity was not confirmed. The
weight of evidence, while not achieving statistical signifi-
cance, was towards a negative association. A negative
association could have several possible explanations. A
plausible mechanism is a subject-specific threshold effect.
Persons who seek care only when their symptoms (e.g.,
dyspnea) are severe will have a low overall rate of exacer-
bation but experience a high proportion of severe exacerba-
tions. Another explanation is reverse causation, in which
severe exacerbation might result in a change (e.g., intensifi-
cation) of care, which may reduce the rate of subsequent
exacerbations. A third explanation is that severe exacerba-
tions and mild/moderate exacerbations are different (but
related) phenotypes with different etiologies and molecular
drivers.
To our knowledge, ours is the first study to have used a
frailty model to quantify the extent of heterogeneity in the
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Figure 2. Individualized rate of chronic obstructive pulmonary disease (COPD) exacerbation (episodes/year) (A) and individualized ratio of
severe exacerbations to total exacerbations (B), MACRO Study, 2006–2010. Values are model-estimated βδ +δe X z. . .i i for the rate component and
( + )β′ β′+ ′ + ′e e/ 1X Xz z. .i ii i for the severity component (see text and Web Appendix 1 for full description). Values for random-effect terms (zi and ′z i)
were obtained using the empirical Bayes method, implemented with the PREDICT statement of SAS PROC NLMIXED.
Table 3. Results From Sensitivity Analyses of Rate-Severity Models of Chronic Obstructive Pulmonary Disease Exacerbations, MACRO
Study, 2006–2010
Scenario
Effect of
Treatment
on Rate
Effect of
Treatment on
Severity
Correlation Coefficient
for Rate and Severity
CV for
Exacerbation
Rate
CV for the
Probability of
Exacerbation
Being SevereHR 95% CI OR 95% CI ρ 95% CI P Valuea
Death defined as an
eventb
0.77 0.68, 0.89 0.96 0.65, 1.41 −0.20 −0.42, 0.00 0.054 0.68 0.79
Marginal modelsc 0.77 0.67, 0.89 0.92 0.62, 1.36 N/A 0.68 0.85
Abbreviations: CI, confidence interval; CV, coefficient of variation; HR, hazard ratio; N/A, not applicable; OR, odds ratio.
a The P value for the correlation coefficient was calculated using the delta method (default option in the ESTIMATE statement of SAS PROC
NLMIXED).
b Severity coding: 0 = mild or moderate exacerbation; 1 = severe or very severe exacerbation or death.
c Two separate random-effect models were fitted for the rate and severity components.
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COPD exacerbation rate, as well as the first one to have
investigated the presence and extent of heterogeneity in
exacerbation severity. Previously, Hurst et al. (26) evalu-
ated 2,138 COPD patients followed for up to 3 years and
concluded that individuals differed in their rate of exacer-
bations. However, the investigators only partially quanti-
fied the degree of heterogeneity in rate, by categorizing
individuals into those who had 0, 1, and 2 or more exacer-
bations in the first year of follow-up. The occurrence of a
previous exacerbation was the strongest predictor of future
exacerbations in a multinomial regression model for the
categories of exacerbation frequency. Our approach in
modeling exacerbation rate was different in that the varia-
tion in rate that was unexplained by observable charac-
teristics was explicitly modeled through a random-effect
term. In this framework, the previous rate of exacerbation,
while not a covariate in the regression model, carries infor-
mation about the value of the unobserved random-effect
term and thus becomes associated with future exacerba-
tions. In addition, through a second random-effect term, we
captured heterogeneity in the severity of exacerbations and
its relationship with exacerbation rate. The observed het-
erogeneity in exacerbation severity implies that a patient’s
previous history of exacerbation severity (which provides
information about the value of the unobserved random-
effect term for severity) can be informative in determining
the severity of future exacerbations. This framework enabled
us to fully quantify the spectrum of heterogeneity (Figure 2)
and has the capacity to make “individualized” predictions of
the rate, timing, and severity of future exacerbations that
incorporate the uncertainty in the unobserved value of the
random-effect terms in a given patient.
The limitations of the present study should be acknowl-
edged. The confidence interval for the correlation coeffi-
cient between exacerbation rate and severity contained
relatively strong negative values. Studies with larger sam-
ple sizes might be able to provide more precise estimates
of the association between rate and severity. Only patients
with a previous history of COPD exacerbation were
enrolled in the MACRO Study (16). This was to ensure
that there would be enough exacerbations during follow-up
time to provide sufficient statistical power at a reasonable
sample size. This renders the MACRO cohort relatively
homogeneous in terms of exacerbation rate, and it is ex-
pected that heterogeneity will be even higher in the general
COPD population. However, it can be argued that the util-
ity of a risk-stratification tool for future exacerbations is
the greatest among COPD patients who have experienced
exacerbation at least once in the past, thus justifying the use
of estimates based on this sample. Another limitation of the
present study was that we could not model all potentially
relevant clinical characteristics because they were not cap-
tured in MACRO. For instance, previous studies have found
respiratory symptoms (e.g., wheezing), history of gastro-
esophageal reflux, and blood biomarkers (white blood cell
count, fibrinogen) to be associated with exacerbation rate
(26). It is likely that some component of the heterogeneity
in the rate and severity of exacerbations may be explained
by inclusion of these and other covariates. Finally, death is
a competing risk for COPD exacerbation. Fewer than 4% of
participants died during the study, and the sensitivity analy-
sis that included death as an event produced similar results.
In addition to severity, the duration of exacerbations is
another determinant of their burden. Exacerbations can last
for a few days to a few weeks, during which time an indi-
vidual is not at risk for another exacerbation (18). There
are extensions of survival models that can take the duration
of events into account. For example, Xue and Brookmeyer
(27) have proposed bivariate random-effect models that can
jointly model between-episode and within-episode inter-
vals. Yan and Fine (28) employed a “temporal process
regression” framework to model marginal means of the
cumulative number of exacerbations, number of days with
exacerbations, and proportion of follow-up time spent in an
exacerbation episode among patients with cystic fibrosis
(29). Extension of the present method to include exacerba-
tion duration, or extension the above-mentioned methods
to include exacerbation severity, may result in more com-
prehensive models that capture 3 fundamental aspects of
exacerbations: their occurrence, duration, and severity. This
could be the topic of further research.
In addition to variable exacerbation duration, some evi-
dence suggests that COPD patients are more likely to expe-
rience another exacerbation during the period immediately
after a previous one (30). As such, the hazard function is a
complex function of time in the short period after the
occurrence of exacerbations. These temporal changes in
hazard do not, per se, result in biased estimates from a
model for cumulative incidence. However, they may affect
the accuracy of model-based predictions if the patient has
recently experienced an exacerbation. A gap time analysis
could potentially provide more flexibility in modeling post-
exacerbation hazard as well as possible causal associations
between exacerbations (21), but such a model is more suit-
able for predictions related to the next exacerbation than
for characterizing exacerbation history. In addition, the
follow-up time, starting from randomization, is a left-
truncated interval (with unknown duration) in this type of
analysis, causing additional challenges in proper gap-time
model specification. It can be argued that in a total time
model, the randomization time is an arbitrary milestone for
defining time zero. While this is generally a valid concern,
the compatibility of the fitted model with a constant hazard
model makes this argument less relevant in this context.
Bearing these limitations in mind, the results of this
study can have important implications. The findings indi-
cate that COPD patients fall on a 2-dimensional intrinsic
rate-severity spectrum, with significant variability in both
dimensions. The future burden of exacerbations in a patient
can be predicted by knowing where the patient belongs on
this spectrum. This can be partially determined through
observed characteristics and the patient’s previous history
of exacerbations. The significant unexplained variability in
both rate and severity also means that attempts in finding
other predictors (e.g., biomarkers) can potentially signifi-
cantly refine our abilities to risk-stratify patients. Developing
and validating prediction models for such risk stratification
could be the focus of future research.
Despite the devastating burden of COPD, many fea-
tures of the natural history of this disease are not well
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understood. COPD exacerbations (especially severe ones)
are watershed moments in the course of COPD but are
poorly characterized (31). In this analysis, we demonstrated
substantial between-individual variability not only in the
rate of exacerbations but also in the severity of exacerba-
tions. From a methodological perspective, frailty models
for recurrent-event data such as COPD exacerbations are
underutilized. Compared with conventional survival analy-
sis methods, they can more optimally use the available data
and can provide important insights about the extent and de-
terminants of heterogeneity. On a broader scale, more
nuanced analyses of COPD outcomes aimed at improving
our understanding of the natural history of COPD and
enabling risk prediction are required.
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